BAXFENDY Becomes First FDA-Approved Aldosterone Synthase Inhibitor for Adults With Hypertension in the U.S.
AstraZeneca has announced that the U.S. Food and Drug Administration has approved BAXFENDY for the treatment of hypertension in adults whose blood pressure remains inadequately controlled despite the use of other antihypertensive medications. The approval marks a significant milestone in cardiovascular medicine, introducing the first aldosterone synthase inhibitor, or ASI, approved in the United States and offering a new therapeutic approach for millions of patients struggling with persistent hypertension.
The decision represents one of the most notable advancements in hypertension treatment in recent years, particularly because blood pressure management has seen relatively limited innovation over the past two decades despite the continued global burden of cardiovascular disease. AstraZeneca believes the approval of BAXFENDY could address a substantial unmet medical need among patients who continue to experience elevated blood pressure levels even while taking multiple therapies.
Hypertension remains one of the most widespread chronic health conditions worldwide. According to global estimates, approximately 1.4 billion people are currently living with high blood pressure. In the United States alone, around half of patients already receiving multiple antihypertensive medications still struggle to achieve adequate blood pressure control. Persistent hypertension significantly increases the risk of heart attack, stroke, kidney disease, heart failure, dementia, and premature death.
Medical experts continue to describe hypertension as the most important modifiable cardiovascular risk factor globally. Despite the availability of numerous treatment classes—including ACE inhibitors, beta blockers, calcium channel blockers, angiotensin receptor blockers, and diuretics—many patients remain difficult to treat because of complex biological mechanisms contributing to elevated blood pressure.
BAXFENDY introduces a fundamentally different treatment mechanism by specifically targeting aldosterone production. Aldosterone is a hormone produced by the adrenal glands that plays a central role in regulating blood pressure, sodium retention, fluid balance, and potassium levels within the body. Excess aldosterone activity has long been associated with resistant hypertension and increased cardiovascular and kidney complications.
Unlike traditional therapies that indirectly influence hormonal pathways or vascular tone, baxdrostat was designed as a highly selective and potent aldosterone synthase inhibitor that directly blocks the production of aldosterone itself. By reducing aldosterone synthesis, the therapy aims to lower blood pressure while potentially addressing an underlying biological driver of uncontrolled hypertension.
The FDA approval was supported by positive findings from the Phase III BaxHTN clinical trial program, which evaluated the safety and efficacy of BAXFENDY in patients with uncontrolled and resistant hypertension who were already receiving at least two antihypertensive medications. The results demonstrated statistically significant and clinically meaningful reductions in seated systolic blood pressure at both the 2 mg and 1 mg doses compared with placebo.
The Phase III BaxHTN trial, which was published in the New England Journal of Medicine, showed that patients receiving the 2 mg dose of BAXFENDY achieved an average reduction from baseline in seated systolic blood pressure of 15.7 mmHg at week 12. Compared with placebo, the placebo-adjusted reduction was 9.8 mmHg, a result that reached strong statistical significance.
Patients treated with the 1 mg dose also experienced substantial improvements. The average reduction from baseline in seated systolic blood pressure was 14.5 mmHg, while the placebo-adjusted reduction measured 8.7 mmHg. By comparison, patients receiving placebo experienced a reduction of 5.8 mmHg.
Importantly, the blood pressure-lowering effects observed in the trial were consistent across patients with both uncontrolled hypertension and treatment-resistant hypertension, suggesting that the therapy may provide benefits in several difficult-to-manage patient populations.
Dr. Bryan Williams, Chair of Medicine at University College London and primary investigator of the BaxHTN trial, described the approval as an important development for the hypertension field.
Williams noted that clinicians have been waiting for innovative medications such as BAXFENDY for many years because of the persistent challenges associated with treating uncontrolled hypertension. According to him, the therapy’s novel mechanism of action has the potential to transform clinical practice by targeting one of the root causes of persistent blood pressure elevation.
He also highlighted the clinical significance of the nearly double-digit placebo-adjusted reductions in systolic blood pressure achieved in the trial. Epidemiological evidence has consistently shown that a reduction of approximately 10 mmHg in systolic blood pressure may lower the risk of serious cardiovascular events by roughly 20%, underscoring the potential long-term importance of the therapy’s efficacy profile.
Public health advocates also emphasized the broader implications of the approval. John M. Clymer, Executive Director of the National Forum for Heart Disease & Stroke Prevention, described hypertension as a widespread “silent killer” responsible for major cardiovascular and neurological complications.
Clymer stated that tens of millions of individuals continue to struggle with blood pressure control despite lifestyle changes and currently available treatments. He noted that innovative therapies like BAXFENDY may help many patients better protect their heart, kidney, and brain health over time.
AstraZeneca executives similarly positioned the approval as a major advancement for patients with limited treatment options. Ruud Dobber, Executive Vice President of AstraZeneca’s BioPharmaceuticals Business Unit, stated that BAXFENDY offers a much-needed first-in-class innovation for patients whose hypertension remains uncontrolled despite existing therapies or who are unable to tolerate currently available medicines.
Dobber emphasized that approximately 23 million patients in the United States remain uncontrolled despite treatment with two or more antihypertensive medications. He also pointed out that hypertension treatment has experienced relatively little therapeutic innovation over the last twenty years, making the approval of a novel mechanistic therapy particularly meaningful.
In addition to efficacy findings, AstraZeneca released detailed safety information for BAXFENDY. As with many therapies affecting hormonal and electrolyte regulation, monitoring of certain laboratory parameters will be important during treatment.
One of the key warnings associated with the medication involves hyperkalemia, or elevated potassium levels. Because aldosterone plays a role in potassium balance, inhibiting its production may increase the risk of hyperkalemia in some patients. AstraZeneca recommends assessment of serum potassium levels prior to treatment initiation and periodic monitoring throughout therapy.
Patients considered at elevated risk for hyperkalemia include older adults, individuals with diabetes, patients with chronic kidney disease, and those receiving medications that may increase potassium levels. If clinically significant hyperkalemia develops, physicians may need to interrupt or discontinue treatment.
The therapy also carries a warning regarding hyponatremia, or low sodium levels. Serum sodium concentrations should be evaluated before starting treatment and monitored periodically during therapy, especially in patients with low baseline sodium levels or increased susceptibility to electrolyte abnormalities.
The most commonly reported adverse reactions in pooled placebo-controlled studies included hyperkalemia, hypotension, hyponatremia, dizziness, and muscle spasms. The incidence of hyperkalemia was higher among patients receiving the 2 mg dose compared with placebo, reflecting the medication’s hormonal mechanism.
AstraZeneca also noted potential drug interaction considerations. Because BAXFENDY is metabolized through the CYP3A pathway, strong or moderate CYP3A inducers may reduce therapeutic effectiveness and require additional monitoring. Concurrent use with medications that impair potassium secretion or increase potassium levels may also elevate the risk of hyperkalemia.
The approved indication specifies that BAXFENDY should be used in combination with other antihypertensive therapies for adults whose blood pressure remains uncontrolled on existing medications. AstraZeneca stated that lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, particularly strokes and myocardial infarctions.
The recommended standard dose of BAXFENDY is 2 mg orally once daily. However, patients considered at higher risk for hyperkalemia or hyponatremia may begin treatment at a lower 1 mg daily dose.
The approval of BAXFENDY may also have broader implications for future cardiovascular drug development. Aldosterone has increasingly attracted scientific interest because of its role not only in hypertension but also in cardiovascular remodeling, inflammation, fibrosis, and kidney disease progression. By successfully targeting aldosterone synthesis directly, AstraZeneca has introduced a new therapeutic class that could potentially expand into additional cardiometabolic and renal indications over time.
For now, however, the approval primarily represents a potentially important new option for patients with difficult-to-control hypertension, a population that continues to face substantial cardiovascular risk despite widespread treatment availability. With millions of patients unable to achieve adequate blood pressure control using current therapies, AstraZeneca’s first-in-class aldosterone synthase inhibitor could reshape treatment strategies and provide physicians with a new tool to combat one of the world’s leading causes of death and disability.
